Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Happel

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|May 26, 2017
Minimally invasive local ablative therapies in combination with radioiodine therapy in benign thyroid disease: preparation, feasibility and efficiency - preliminary resultsAlexander Mader, Oscar Maximilian Mader, Daniel Gröner, et al.
Thyroid : Official Journal of the American Thyroid Association|April 30, 2014
Evaluation of fear of radiation and isolation before and after radioiodine therapyFriederike von Müller, Christian Happel, Jörg Reinhardt, et al.
Cancers|September 28, 2023
Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate CancerNicolai Mader, Christina Schoeler, Niloufar Pezeshkpour, et al.
European Journal of Radiology|October 26, 2016
Cooled microwave ablation of thyroid nodules: Initial experienceYücel Korkusuz, Oscar Maximilian Mader, Wolfgang Kromen, et al.
Nuklearmedizin. Nuclear Medicine|February 16, 2022
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, et al.
Cancers|August 27, 2021
Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow InvolvementDaniel Groener, Justus Baumgarten, Sebastian Haefele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2023
Extended therapy with [<sup>177</sup>Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancerNicolai Mader, Christina Nguyen Ngoc, Bilge Kirkgöze, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Cancers|February 15, 2022
Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-DichlorideJustus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, et al.
Cancers|August 12, 2023
Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CTDaniel Groener, Jennifer Wichert, Magdalena Adams, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|May 26, 2017
Minimally invasive local ablative therapies in combination with radioiodine therapy in benign thyroid disease: preparation, feasibility and efficiency - preliminary resultsAlexander Mader, Oscar Maximilian Mader, Daniel Gröner, et al.
Thyroid : Official Journal of the American Thyroid Association|April 30, 2014
Evaluation of fear of radiation and isolation before and after radioiodine therapyFriederike von Müller, Christian Happel, Jörg Reinhardt, et al.
Cancers|September 28, 2023
Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate CancerNicolai Mader, Christina Schoeler, Niloufar Pezeshkpour, et al.
European Journal of Radiology|October 26, 2016
Cooled microwave ablation of thyroid nodules: Initial experienceYücel Korkusuz, Oscar Maximilian Mader, Wolfgang Kromen, et al.
Nuklearmedizin. Nuclear Medicine|February 16, 2022
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]Wolfgang Tilman Kranert, Benjamin Bockisch, Jennifer Wichert, et al.
Cancers|August 27, 2021
Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow InvolvementDaniel Groener, Justus Baumgarten, Sebastian Haefele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2023
Extended therapy with [<sup>177</sup>Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancerNicolai Mader, Christina Nguyen Ngoc, Bilge Kirkgöze, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Cancers|February 15, 2022
Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-DichlorideJustus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, et al.
Cancers|August 12, 2023
Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CTDaniel Groener, Jennifer Wichert, Magdalena Adams, et al.
Pageof 5